The fact
that mAb tabalumab failed was more or less expected due to mAb’s hype is on its
way down. But chances to fail for fostamatinib were lower. Of course fostamatinib
is a result of the targeted
approach with a sexy “scientific” background:
Fostamatinib is an experimental drug
candidate for the treatment of a variety of diseases. The drug is administered
orally as a disodium salt, and is a prodrug of the active compound tamatinib
(R-406), which is an inhibitor of the enzyme spleen tyrosine kinase (Syk).
Well, what
targeted failure will come next?
No comments:
Post a Comment